For those watching Prosavin, from Oxford Biomedica, the six-month endpoint results are expected to be released tomorrow and Friday, November 13 and 14. Results at three months were very positive, with improvements of 30% in all three treated patients, and this was at a very low dose. Here's the link:

"The primary efficacy endpoint of the study is based on the UPDRS Part III (motor score) assessment at six months after treatment. The principal investigator for the trial, Professor Stéphane Palfi from the Henri Mondor Hospital in Paris, intends to report the detailed interim results of the study, which may include the six-month UPDRS data and the imaging study performed at the Commissariat à l’Energie Atomique and Service Hospitalier Frédéric Joliot in Orsay, at the 16th Annual Congress of the European Society of Gene and Cell Therapy in Bruges, Belgium, on 13-16 November 2008........"

http://www.bioportfolio.com/biotech_...oMedica_55.htm